Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Rakovina Therapeutics Inc. is participating in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City, where key executives will present the company's R&D pipeline and corporate strategy [1][2][4]. Company Overview - Rakovina Therapeutics is a biopharmaceutical company focused on developing innovative cancer treatments using AI-powered drug discovery technologies, specifically the Deep-Docking™ and Enki™ platforms [6][7]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]. Recent Corporate Highlights - The company has achieved significant milestones in 2025, including presenting new preclinical data at the AACR Annual Meeting and obtaining DTC eligibility to enhance market accessibility for U.S. investors [3][8]. - Rakovina has advanced its KT-5000AI program, yielding potent ATR inhibitor candidates through AI-enabled screening [8]. - A non-binding Letter of Intent has been announced with Saudi-based NanoPalm Ltd. to form a joint venture that combines AI-discovered oncology therapeutics with patterned lipid nanoparticle delivery systems [8].